JP2022526842A - 脂質ベースのナノ粒子および最適化されたインスリン投薬レジメンにおけるその使用方法 - Google Patents

脂質ベースのナノ粒子および最適化されたインスリン投薬レジメンにおけるその使用方法 Download PDF

Info

Publication number
JP2022526842A
JP2022526842A JP2021559986A JP2021559986A JP2022526842A JP 2022526842 A JP2022526842 A JP 2022526842A JP 2021559986 A JP2021559986 A JP 2021559986A JP 2021559986 A JP2021559986 A JP 2021559986A JP 2022526842 A JP2022526842 A JP 2022526842A
Authority
JP
Japan
Prior art keywords
insulin
biotin
administered
subject
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021559986A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020210697A5 (enExample
Inventor
ダブリュ． ブレア ゲオ
Original Assignee
エスディージー インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エスディージー インコーポレイテッド filed Critical エスディージー インコーポレイテッド
Publication of JP2022526842A publication Critical patent/JP2022526842A/ja
Publication of JPWO2020210697A5 publication Critical patent/JPWO2020210697A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021559986A 2019-04-12 2020-04-10 脂質ベースのナノ粒子および最適化されたインスリン投薬レジメンにおけるその使用方法 Pending JP2022526842A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962833228P 2019-04-12 2019-04-12
US62/833,228 2019-04-12
US202062988748P 2020-03-12 2020-03-12
US62/988,748 2020-03-12
PCT/US2020/027762 WO2020210697A1 (en) 2019-04-12 2020-04-10 Lipid-based nanoparticles and use of same in optimized insulin dosing regimens

Publications (2)

Publication Number Publication Date
JP2022526842A true JP2022526842A (ja) 2022-05-26
JPWO2020210697A5 JPWO2020210697A5 (enExample) 2023-04-17

Family

ID=72748579

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021559986A Pending JP2022526842A (ja) 2019-04-12 2020-04-10 脂質ベースのナノ粒子および最適化されたインスリン投薬レジメンにおけるその使用方法

Country Status (7)

Country Link
US (3) US10918700B2 (enExample)
EP (1) EP3952904A4 (enExample)
JP (1) JP2022526842A (enExample)
AU (1) AU2020271901A1 (enExample)
CA (1) CA3136665A1 (enExample)
WO (1) WO2020210697A1 (enExample)
ZA (1) ZA202108217B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
US20210137838A1 (en) * 2017-03-13 2021-05-13 Sdg, Inc. Lipid-based nanoparticles with enhanced stability

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006540A1 (en) * 1988-01-13 1989-07-27 Technology Unlimited, Inc. Diabetic control by combined insulin forms
JP2002515417A (ja) * 1998-05-19 2002-05-28 エスディジー、インコーポレイテッド 標的指向リポソーム薬剤送達システム
JP2009507761A (ja) * 2005-05-23 2009-02-26 エスデイージー・インコーポレーテツド インスリンを哺乳動物に送達するための脂質構築物
WO2018169954A1 (en) * 2017-03-13 2018-09-20 Sdg, Inc. Lipid-based nanoparticles with enhanced stability
JP2020537138A (ja) * 2017-11-09 2020-12-17 ヴィオニア スウェーデン エービー 車両レーダシステムを用いた駐車列の検出

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1325126C (zh) * 2001-11-16 2007-07-11 梅德创新股份公司 医药用的泵装置
EP1858545A2 (en) * 2005-03-04 2007-11-28 Curedm Inc. Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
US20110135725A1 (en) * 2005-05-23 2011-06-09 Sdg, Inc. Lipid Construct for Delivery of Insulin to a Mammal
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US20120035105A1 (en) 2009-01-09 2012-02-09 Sdg, Inc. Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
EP2727587A1 (en) * 2012-10-30 2014-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
AU2019205795A1 (en) 2018-01-05 2020-07-09 Sdg, Inc. Compositions comprising lipid-based nanoparticles for treating diabetes mellitus

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006540A1 (en) * 1988-01-13 1989-07-27 Technology Unlimited, Inc. Diabetic control by combined insulin forms
JP2002515417A (ja) * 1998-05-19 2002-05-28 エスディジー、インコーポレイテッド 標的指向リポソーム薬剤送達システム
JP2009507761A (ja) * 2005-05-23 2009-02-26 エスデイージー・インコーポレーテツド インスリンを哺乳動物に送達するための脂質構築物
WO2018169954A1 (en) * 2017-03-13 2018-09-20 Sdg, Inc. Lipid-based nanoparticles with enhanced stability
JP2020537138A (ja) * 2017-11-09 2020-12-17 ヴィオニア スウェーデン エービー 車両レーダシステムを用いた駐車列の検出

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
'STUDY OF HDV INSULIN VERSUS INSULIN IN TYPE 1 DIABETES SUBJECTS(ISLE-1)(ISLE-1)',［ONLINE］, JPN6024011479, 2018, ISSN: 0005441353 *

Also Published As

Publication number Publication date
US20210379160A1 (en) 2021-12-09
US20240139288A1 (en) 2024-05-02
WO2020210697A1 (en) 2020-10-15
AU2020271901A1 (en) 2021-11-04
ZA202108217B (en) 2023-12-20
US20200323961A1 (en) 2020-10-15
CA3136665A1 (en) 2020-10-15
US10918700B2 (en) 2021-02-16
EP3952904A1 (en) 2022-02-16
EP3952904A4 (en) 2022-12-28

Similar Documents

Publication Publication Date Title
JP7656353B2 (ja) 向上した安定性を有する脂質ベースのナノ粒子
JP2023166021A (ja) インスリン分泌促進性ペプチドの懸濁製剤及び使用
US20240108585A1 (en) Compositions comprising lipid-based nanoparticles for treating diabetes mellitus
JP2011006428A (ja) インスリン組成物および組成物の製造方法
US20240139288A1 (en) Lipid-based nanoparticles and use of same in optimized insulin dosing regimens
US11077173B2 (en) Lipid-based nanoparticles and methods using same
JP7752343B2 (ja) 経口ペプチド投与
HK40015408A (en) Lipid-based nanoparticles with enhanced stability

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230407

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230531

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240626

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241021